Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs iShares MSCI Singapore ETF (EWS) Price & Performance

BridgeBio Pharma IncTrade
iShares MSCI Singapore ETFTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs iShares MSCI Singapore ETF — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while iShares MSCI Singapore ETF trades at $34.04. The key difference: iShares MSCI Singapore ETF is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.

BBIOEWS
Market Cap
$16.36B
Sector
HealthBroad Market / Factor
52-Week High
$90.17$33.92
52-Week Low
$47.29$26.71
Enterprise Value
$18.14B

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About iShares MSCI Singapore ETF

EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.

Read more on EWS